Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) major shareholder Financial Lp Hrt sold 225,191 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $0.12, for a total value of $27,022.92. Following the transaction, the insider owned 1,838,075 shares of the company’s stock, valued at approximately $220,569. This trade represents a 10.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Wednesday, June 10th, Financial Lp Hrt bought 2,159,052 shares of Clearmind Medicine stock. The shares were acquired at an average price of $0.15 per share, with a total value of $323,857.80.
Clearmind Medicine Stock Performance
Clearmind Medicine stock opened at $3.34 on Friday. The stock has a market cap of $3.41 million, a P/E ratio of -0.02 and a beta of 0.64. The stock has a 50 day moving average of $6.22 and a 200-day moving average of $16.92. Clearmind Medicine Inc. has a 52 week low of $2.10 and a 52 week high of $524.00.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded Clearmind Medicine to a “sell” rating in a research note on Saturday, May 23rd.
View Our Latest Analysis on Clearmind Medicine
Clearmind Medicine Company Profile
Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.
Clearmind’s pipeline includes multiple preclinical and early clinical candidates.
Featured Stories
- Five stocks we like better than Clearmind Medicine
- TJX: Retail’s Apex Predator Feasts on Inflation
- MarketBeat Week in Review – 06/08 – 06/12
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
